Evaluation of the radiocobalt-labeled [MMA-DOTA-Cys61]-Z HER2:2395-Cys affibody molecule for targeting of HER2-expressing tumors

Molecular Imaging and Biology

Volumn 12, Issue 1, 2010, Pages 54-62

  Wållberg, Helena ^a   Ahlgren, Sara ^b   Widström, Charles ^c   Orlova, Anna ^a,d  

^a Affibody AB   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

Author keywords

Affibody molecule; Cobalt; HER2; Imaging; PET

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; COBALT 57; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INDIUM 111; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ARTICLE; ASCITES TUMOR; CANCER CELL CULTURE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; LIVER METASTASIS; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY ADENOCARCINOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BINDING; RADIOACTIVITY; STOMACH ADENOCARCINOMA; TUMOR XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; COBALT RADIOISOTOPES; GAMMA CAMERAS; HUMANS; MICE; MICE, NUDE; NEOPLASMS; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANIMALIA; MUS;

EID: 77149122098     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-009-0238-8     Document Type: Article

References (30)

1. V Tolmachev A Orlova FY Nilsson, et al. 2007 Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy Expert Opin Biol Ther 7 555 568 10.1517/14712598.7.4.555 1:CAS:528:DC%2BD2sXjt1yns78%3D 17373906 (Pubitemid 46524679)
2. A Orlova J Feldwisch L Abrahmsén V Tolmachev 2007 Update: affibody molecules for molecular imaging and therapy for cancer Cancer Biother Radiopharm 22 573 584 10.1089/cbr.2006.004-U 1:CAS:528:DC%2BD2sXht1GrsLvK 17979560 (Pubitemid 350058993)
3. FY Nilsson V Tolmachev 2007 Affibody molecules: new protein domains for molecular imaging and targeted tumor therapy Curr Opin Drug Discov Devel 10 167 175 1:CAS:528:DC%2BD2sXktVOntrw%3D 17436552
4. A Orlova M Magnusson TL Eriksson, et al. 2006 Tumor imaging using a picomolar affinity HER2 binding affibody molecule Cancer Res 66 4339 4348 10.1158/0008-5472.CAN-05-3521 1:CAS:528:DC%2BD28XjsFSltbs%3D 16618759
5. S Masood MM Bui 2000 Assessment of Her-2/neu overexpression in primary breast cancers and their metastatic lesions: an immunohistochemical study Ann Clin Lab Sci 30 259 265 1:CAS:528:DC%2BD3cXmtVeqtLg%3D 10945565
6. R Simon A Nocito T Hubscher, et al. 2001 Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer J Natl Cancer Inst 93 1141 1146 10.1093/jnci/93.15.1141 1:CAS:528:DC%2BD3MXmtVGqsLc%3D 11481385
7. RC Bast Jr P Ravdin DF Hayes, et al. 2001 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology J Clin Oncol 19 1865 1878 11251019
8. R Molina V Barak A van Dalen, et al. 2005 Tumor markers in breast cancer-European Group on Tumor Markers recommendations Tumour Biol 26 281 293 10.1159/000089260 16254457 (Pubitemid 41619458)
9. 111In- benzyl-DTPA-ZHER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors J Nucl Med 47 846 853 1:CAS:528: DC%2BD28XltFaiu74%3D 16644755 (Pubitemid 46772889)
10. A Orlova V Tolmachev R Pehrson, et al. 2007 Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors Cancer Res 67 2178 2186 10.1158/0008-5472.CAN-06-2887 1:CAS:528:DC%2BD2sXitlSjs78%3D 17332348 (Pubitemid 46424237)
11. S Ahlgren A Orlova D Rosik, et al. 2008 Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant Affibody molecules Bioconjug Chem 19 235 243 10.1021/bc700307y 1:CAS:528:DC%2BD1cXntV2g 18163536 (Pubitemid 351213855)
12. V Tolmachev H Xu H Wållberg, et al. 2008 Evaluation of maleimido derivative of CHX-A" DTPA for site-specific labeling of Affibody molecules Bioconjug Chem 19 1579 1587 10.1021/bc800110y 1:CAS:528:DC%2BD1cXosVejtrw%3D 18620447
13. HER2:342, an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors Bioconjug Chem 18 1956 1964 10.1021/bc7002617 1:CAS:528:DC%2BD2sXhtF2gsrvF 17944527 (Pubitemid 350219996)
14. 99mTc-labelled Affibody molecules with reduced renal uptake Eur J Nucl Med Mol Imaging 35 12 2245 2255 10.1007/s00259-008-0845- 7 1:CAS:528:DC%2BD1cXhsVyls73J 18594815
15. Z Cheng OP De Jesus M Namavari, et al. 2008 Small-animal PET imaging of human epidermal growth factor receptor type 2 expression with site-specific 18F-labeled protein scaffold molecules J Nucl Med 49 804 813 10.2967/jnumed.107.047381 1:CAS:528:DC%2BD1cXmvVSju7o%3D 18413392 (Pubitemid 351717547)
16. HER2:342-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography Eur J Nucl Med Mol Imaging 35 1008 1018 10.1007/s00259-007-0658-0 1:CAS:528:DC%2BD1cXkvVyjuro%3D 18157531
17. H Lundqvist V Tolmachev 2002 Targeting peptides and positron emission tomography Biopolymers 66 381 392 10.1002/bip.10348 1:CAS:528: DC%2BD3sXislOqsbo%3D 12658725 (Pubitemid 36433533)
18. HM Jansen J Pruim AM van der Vliet, et al. 1994 Visualization of damaged brain tissue after ischemic stroke with cobalt-55 positron emission tomography J Nucl Med 35 456 460 1:STN:280:DyaK2c7lslKksQ%3D%3D 8113896
19. HM Jansen AC Willemsen LG Sinnige, et al. 1995 Cobalt-55 positron emission tomography in relapsing-progressive multiple sclerosis J Neurol Sci 132 139 145 10.1016/0022-510X(95)00139-S 1:STN:280:DyaK28%2FpvVKjsA%3D%3D 8543939
20. 55Co-EDTA for renal imaging using positron emission tomography (PET): a feasibility study Nucl Med Biol 27 77 81 10.1016/S0969-8051(99)00077-3 1:CAS:528: DC%2BD3cXhtFaluro%3D 10755649 (Pubitemid 30099618)
21. A Heppeler JP André I Buschmann, et al. 2008 Metal-ion-dependent biological properties of a chelator-derived somatostatin analogue for tumor targeting Chemistry 14 3026 3034 10.1002/chem.200701264 1:CAS:528: DC%2BD1cXltVartbs%3D 18246556
22. 177Lu] pertuzumab: experimental studies on targeting of HER-2 positive tumour cells Eur J Nucl Med Mol Imaging 32 1457 1462 10.1007/s00259-005-1902-0 1:CAS:528:DC%2BD2MXht1ygu7%2FJ 16193312 (Pubitemid 41746851)
23. DE Milenic K Garmestani ED Brady, et al. 2004 Targeting of HER2 antigen for the treatment of disseminated peritoneal disease Clin Cancer Res 10 7834 7841 10.1158/1078-0432.CCR-04-1226 1:CAS:528:DC%2BD2cXhtVCrs7zJ 15585615 (Pubitemid 39587521)
24. E Lundberg I Höidén-Guthenberg B Larsson, et al. 2007 Site-specifically conjugated anti-HER2 Affibody molecules as one-step reagents for target expression analyses on cells and xenograft samples J Immunol Methods 319 53 63 10.1016/j.jim.2006.10.013 1:CAS:528:DC%2BD2sXntlyqsw%3D%3D 17196217 (Pubitemid 46107467)
25. T Lindmo E Boven F Cuttitta, et al. 1984 Determination of the immunoractive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess J Immunol Methods 72 77 89 10.1016/0022-1759(84)90435-6 1:CAS:528:DyaL2cXlt1ymsrg%3D 6086763 (Pubitemid 14091996)
26. HER2:342, an affibody ligand conjugate for targeting of HER2-expressing malignant tumors Q J Nucl Med Mol Imaging 51 314 323 1:STN:280:DC%2BD2srps1OgtQ%3D%3D 17464277
27. HER2:342, a potential agent for imaging of HER2 expression in malignant tumors Int J Mol Med 20 397 404 1:CAS:528:DC%2BD2sXhtVWqtbjO 17671747
28. M Ginj H Zhang B Waser, et al. 2006 Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors Proc Natl Acad Sci U S A 103 16436 16441 10.1073/pnas.0607761103 1:CAS:528:DC%2BD28Xht1WmsLjJ 17056720 (Pubitemid 44715214)
29. 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems J Nucl Med 48 1327 1337 10.2967/jnumed.107.039487 1:CAS:528: DC%2BD2sXhtVSktbzP 17631556 (Pubitemid 47242799)
30. 2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues Proc Natl Acad Sci U S A 104 12462 12467 10.1073/pnas.0705347104 1:CAS:528:DC%2BD2sXos1ehtLw%3D 17626788 (Pubitemid 47206160)